Acurx Pharmaceuticals receives Nasdaq minimum bid price deficiency notice; 180-day cure period

Acurx Pharmaceuticals, Inc.

Stock closed below $1.00 for 31 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency.
Company has until August 25, 2025 to regain compliance by closing at $1.00 or higher for 10 consecutive business days.
If compliance not met, Company may seek a second 180-day period via a reverse stock split if other listing standards are met.
No immediate effect on listing; stock continues trading on Nasdaq Capital Market under symbol 'ACXP'.
Company intends to monitor bid price and consider available options but can provide no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.